Arax Advisory Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

Arax Advisory Partners’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69	Hold	26	–	–	﹤0.01%	5150
2026 Q1	$61	Hold	26	–	–	﹤0.01%	3648
2025 Q4	$55	Hold	26	–	–	﹤0.01%	3906
2025 Q3	$44	Buy	+26	New	+$36	﹤0.01%	3540

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Arax Advisory Partners's ABOS Position: Q2 2026 in Review

Arax Advisory Partners held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 26 shares worth $69. The position accounts for ﹤0.01% of the portfolio, ranked #5150.

Arax Advisory Partners first reported a position in ABOS in Q3 2025 and has held it in 4 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Arax Advisory Partners held 26 shares of Acumen Pharmaceuticals worth $69 as of Q2 2026.
Arax Advisory Partners left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5150 holding.
Arax Advisory Partners first reported a position in Acumen Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.